A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream treatments have not changed for decades. To identify additional therapeutic targets in AML, we optimize a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening platform...

Full description

Bibliographic Details
Main Authors: Konstantinos Tzelepis, Hiroko Koike-Yusa, Etienne De Braekeleer, Yilong Li, Emmanouil Metzakopian, Oliver M. Dovey, Annalisa Mupo, Vera Grinkevich, Meng Li, Milena Mazan, Malgorzata Gozdecka, Shuhei Ohnishi, Jonathan Cooper, Miten Patel, Thomas McKerrell, Bin Chen, Ana Filipa Domingues, Paolo Gallipoli, Sarah Teichmann, Hannes Ponstingl, Ultan McDermott, Julio Saez-Rodriguez, Brian J.P. Huntly, Francesco Iorio, Cristina Pina, George S. Vassiliou, Kosuke Yusa
Format: Article
Language:English
Published: Elsevier 2016-10-01
Series:Cell Reports
Subjects:
CRISPR
genetic screen
genetic vulnerability
acute myeloid leukemia
AML
KAT2A
MB-3
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124716313353

Internet

http://www.sciencedirect.com/science/article/pii/S2211124716313353

Similar Items